Hi there madamswer The answers i'd be seeking would be regarding...

Hi there madamswer

The answers i'd be seeking would be regarding 2 points angelus512 raised:

C) What I'm not familiar with and I'd love a response from somebody knowledgable is the Genzyme and Boston Scientific terminating agreements with osiris for the same drug we plan to sell.....that isn't comforting. If it was any good why did Genzyme and BSci not move forward?

D) I've myself often made mention about MSB failing to sell Prochymal in the 2 countries it has approval to do so. I fail to see why MSB wouldn't do that as its not going to effect the FDA or any other country but would provide a good platform to demonstrate its a good drug and would give the stock some positive impetus

Bullet point C is really worrying;why has Mesoblast acquired Prochymal when two other biotechs have walked away from it due poor clinical results.

Also point D is of concern, why isn't the company selling Prochymal if it has been approved in Canada and NZ, seems very odd. They have the greenlight to make money and advance the interests of shareholders but refrain from doing so. Not encouraging really.

regarding other issues, the glaring lack of communication re Phase 3 CHF trial recruitment, the JCR mess, lack of concrete details regarding meetings with the FDA.

thank you for your initiative and willingness to do this.

P.S

my email is [email protected] - I was wondering if you could write me as I wanted to ask you a few investment questions if that's okay.